Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 2—February 2005
Perspective

Managing Febrile Respiratory Illnesses during Hypothetical SARS Outbreaks

Kamran Khan*Comments to Author , Peter Muennig†, Michael Gardam‡, and Joshua Graff Zivin†
Author affiliations: *St. Michael’s Hospital, Toronto, Ontario, Canada; †Columbia University, New York, New York, USA; ‡University Health Network, Toronto, Ontario, Canada

Main Article

Table 1

Selected costs in the decision-analysis model*

Costs† Low Base High Source
Vaccines and medications
Influenza vaccine $10.00 $27.78 $40.00 11
Antibiotics for FRI‡ $30.00 $64.72 $80.00 12
Medical care§
Ambulatory clinic visit $40.00 $60.03 $80.00 13
Hospitalization for FRI $5,000 $11,645 $15,000 14
Hospitalization for influenza $7,500 $17,465 $25,000 14
Hospitalization for PUI $15,000 $19,441 $25,000 14
Hospitalization for SARS $20,000 $28,502 $40,000 14,15
Diagnostic tests
Rapid influenza test $15.00 $26.86 $40.00 16
Multiplex¶ RT-PCR $50.00 $154.02 $200.00 Prodesse Inc., pers. comm.
SARS# RT-PCR $20.00 $54.80 $100.00 Prodesse Inc., pers. comm.
Miscellaneous
Patient time (per hour) $15.00 $24.55 $30.00 17
Contact investigation (per SARS contact) $100.00 $222.94 $300.00 5,18

*FRI, febrile respiratory illness; PUI, person under investigation (for SARS); SARS, severe acute respiratory syndrome; RT-PCR, reverse transcription–polymerase chain reaction.
†Medical and nonmedical costs were adjusted to 2004 U.S. dollars by using the Consumer Price Index.
‡Antimicrobial drug costs are based on a 7-day course of oral levofloxacin.
§Includes laboratory tests, transportation costs, and patient time.
¶Detects influenza viruses A and B, respiratory syncytial viruses A and B, parainfluenza viruses 1–3, human metapneumovirus, Legionella pneumophila, L. micdadei, Mycoplasma pneumoniae, Chlamydia pneumoniae, and Bordetella pertussis.
#Detects SARS-associated coronavirus and coronaviruses OC43 and 229E.

Main Article

Page created: April 27, 2011
Page updated: April 27, 2011
Page reviewed: April 27, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external